SCPH — SCPHARMACEUTICAL

Ownership history in MARSHALL WACE, LLP  ·  6 quarters on record

This page tracks every 13F SEC filing in which MARSHALL WACE, LLP reported a position in SCPHARMACEUTICAL (SCPH). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 26,880 -46,330 -63.3% 0.00% $152K —
2025 Q1 ADDED 73,210 +49,564 +209.6% 0.00% $193K —
2024 Q3 REDUCED 23,646 -10,723 -31.2% 0.00% $108K —
2023 Q4 REDUCED 34,369 -18,011 -34.4% 0.00% $215K —
2 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)

Other funds also holding SCPH

As of 2025 Q3 — sorted by position size

Yakira Capital Management, Inc. 3Y 7Y 0.87% ORBIMED ADVISORS LLC 3Y 7Y 0.81% Tejara Capital Ltd 3Y 0.73% Newtyn Management, LLC 3Y 7Y 0.65% APIS CAPITAL ADVISORS, LLC 3Y 7Y 0.55% Rangeley Capital, LLC 0.46% Balanced Rock Investment Advisors LLC 0.34% ALPINE ASSOCIATES MANAGEMENT INC. 3Y 7Y 0.33% Rubric Capital Management LP 3Y 7Y 0.33% GABELLI & Co INVESTMENT ADVISERS, INC. 3Y 7Y 0.28%
← Back to MARSHALL WACE, LLP Holdings